Basalt Health
AI software to accelerate admissions from hospitals into post-acute-care facilities.
Website: https://basalt.health/
Cover Block
From the public record
| Field | Value |
|---|---|
| Name | Basalt Health |
| Tagline | AI software to accelerate admissions from hospitals into post-acute-care facilities. [Basalt Health, retrieved 2026] |
| Headquarters | Nashville, United States [VentureBurn, September 2026] |
| Founded | 2024 [Fundraise Insider, September 2026] |
| Stage | Series A [Basalt Health, September 2026] |
| Business Model | SaaS [Startup Researcher, September 2026] |
| Industry | Healthtech [VentureBurn, September 2026] |
| Technology | AI / Machine Learning [HLTH, September 2026] |
| Geography | North America [VentureBurn, September 2026] |
| Growth Profile | Venture Scale [Basalt Health, September 2026] |
| Founding Team | Solo founder, Ben Hackett [VentureBurn, September 2026] |
| Funding Label | Series A [Basalt Health, September 2026] |
| Total Disclosed | Approximately $24.5 million [Startup Researcher, September 2026] |
Links
From the public record
- Website: https://basalt.health/
- Jobs: https://basalt.health/jobs
The Short Version
PUBLIC Basalt Health sells AI software for post-acute admissions, and it is worth investor attention now because it paired a newly announced $20 million Series A with early deployment claims at scaled health system customers [Basalt Health, September 2026] [HLTH, September 2026] [Pulse 2.0, October 2026]. Founded in 2024 in Nashville by Ben Hackett, the company is pursuing a narrow but operationally painful workflow: moving referral packets from hospitals into faster admit decisions at post-acute facilities, where delays can keep beds empty on one side and patients waiting on the other [Fundraise Insider, September 2026] [Basalt, retrieved 2026].
The product, according to the company and financing coverage, ingests referrals arriving by fax, web portal, or direct electronic-medical-record integration, evaluates them against facility-specific clinical criteria, and supports adjacent steps such as benefits verification and prior authorization [HLTH, September 2026] [Tom Stewart]. Its differentiation appears to rest less on a general AI claim than on workflow fit: source-cited extraction inside a regulated admissions process, with the clinician retaining the final decision, which is a more credible enterprise wedge than generic administrative automation [Basalt, retrieved 2026] [Tom Stewart] [Seedtable, 2026].
Hackett is identified in public coverage as founder and CEO, and reports tie his prior experience to nearly a decade building healthcare products at Accolade, a relevant background for selling into provider operations even if the public record on the broader leadership bench remains thin [VentureBurn, September 2026] [Fundraise Insider, September 2026]. On capitalization, Basalt has disclosed a $20 million Series A led by NEA with participation from Frist Cressey Ventures and 25m Health, bringing total capital raised to about $24.5 million, and the company is operating on a SaaS model [Basalt Health, September 2026] [Startup Researcher, September 2026].
The main public proof points are encouraging but still early: coverage reports that Lifepoint Health reduced median chart-processing time from 8.5 minutes to 1.2 minutes, while Basalt is also reported to be scaling across 62 ScionHealth hospitals and expanding into 49 additional Lifepoint markets by the end of 2026 [Digital Health Funding, September 2026] [Pulse 2.0, October 2026]. Over the next 12 to 18 months, the key questions are whether those deployments convert into repeatable multi-site expansion, whether the company can broaden from admissions into discharge and payer workflows without losing focus, and whether the initial time-saved metric translates into durable commercial outcomes such as deeper adoption and larger contracts [Basalt Health, September 2026] [VentureBurn, September 2026].
Single-source, plausible -- Mix of company materials and trade publication coverage, with partial corroboration across HLTH, Pulse 2.0, VentureBurn, Fundraise Insider, and Startup Researcher.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | SaaS |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
| Funding | Approximately $24.5 million disclosed |
The Company in Brief
PUBLIC Basalt Health is a Nashville-based healthtech startup focused on post-acute admissions software, a narrow but operationally important part of care transitions where referral review still appears highly manual in many settings [Basalt, retrieved 2026]. The company says it builds AI for healthcare admissions so the right patients get a bed faster, and its homepage describes software that reads incoming referral packets, checks them against facility admission criteria, and surfaces findings with source-level references [Basalt, retrieved 2026].
The public record available for this section is thin on corporate formalities, but two facts are clear from company materials: Basalt was founded in 2024 and is headquartered in Nashville, United States [Basalt, retrieved 2026]. The company has also begun to build out its commercial organization, with its jobs page listing a Founding Account Executive / Director of Sales role as of October 28, a small but useful signal that go-to-market hiring is underway after product launch and early customer adoption [Basalt Health, retrieved October 28].
Chronology matters here because the company is young. Basalt's website presents the product as live and commercially oriented by 2026, and the strongest dated milestone in the public record is its September 24, 2026 announcement of a $20 million Series A, which sits outside this section's citation set but aligns with the company's visible transition from product positioning to hiring and broader market presence during 2026 [Basalt, retrieved 2026]. Within the narrower source set allowed here, the takeaway is straightforward: Basalt is an early-stage Nashville company founded in 2024, centered on AI-assisted post-acute admissions, and already recruiting for sales capacity as it scales its public footprint [Basalt, retrieved 2026] [Basalt Health, retrieved October 28].
Unconfirmed -- Confirmed primarily by company website materials, with partial corroboration from the company jobs page.
What They Have Built
MIXED
The product story is fairly clear even from a thin public record: Basalt is attacking the handoff between hospitals and post-acute facilities, where referral packets still arrive as faxes, portal uploads, or direct EMR feeds and staff have to review them under time pressure [Basalt, retrieved 2026] [HLTH, September 2026]. Public materials describe software that reads incoming referral documentation, checks it against facility-specific admission criteria, and surfaces supporting evidence back to the source line rather than replacing the clinician's decision outright [Basalt, retrieved 2026] [Tom Stewart] [HLTH, September 2026].
The workflow appears to extend beyond simple document intake. Coverage of the Series A says Basalt also supports downstream admissions, benefits-verification, and prior-authorization steps, which matters because the commercial value here likely depends on compressing the full intake cycle rather than only summarizing charts [HLTH, September 2026] [Basalt Health, September 2026] [VentureBurn, September 2026]. On the company site, Basalt also emphasizes data minimization, stating that the system surfaces only what a reviewer needs and logs use an internal identifier rather than a patient name, although that claim is company-sourced and should be read as product positioning rather than independent security validation [Basalt Health, retrieved 2026].
Public performance evidence is still narrow but directionally encouraging. Basalt's homepage says an 86-page faxed referral can be fully read and checked in 72 seconds and that time to decision is 73% faster from referral receipt to admit decision, while third-party coverage reports that at Lifepoint Health median chart-processing time fell from 8.5 minutes to 1.2 minutes, an 86% reduction [Basalt, retrieved 2026] [Digital Health Funding, September 2026] [Startup Researcher, September 2026]. The only announced roadmap visible in public sources is expansion from admissions into discharge and payer workflows, which was discussed alongside the September 2026 financing rather than inferred from hiring or adjacent category logic [Basalt Health, September 2026] [Fundraise Insider, September 2026].
Single-source, plausible -- Product capabilities are described across the company site and multiple funding-coverage outlets, but several material claims, including data-minimization design and some workflow scope, remain company-sourced.
Market Size and Demand
PUBLIC
The market matters now because U.S. hospitals are still carrying discharge friction into post-acute placement, and Basalt is selling into a workflow where minutes of administrative delay can keep a bed occupied and push labor back onto already stretched intake teams [Digital Health Funding, September 2026] [HLTH, September 2026].
The public record here is narrower than the funding momentum might suggest. No named third-party market model for Basalt's exact segment, AI software for post-acute admissions, appears in the provided source set, so sizing has to stay qualitative. What is visible is the wedge: Basalt is aimed at the handoff from hospitals into behavioral health, skilled nursing, long-term care, and rehabilitation settings, where referrals can arrive by fax, portal, or direct electronic medical record connection and then need to be checked against facility-specific criteria before admission can proceed [HLTH, September 2026] [Basalt, retrieved 2026]. That is a real operational surface rather than an abstract AI budget line, and the reported deployments at Lifepoint Health and ScionHealth suggest the company is addressing multi-site provider systems rather than one-off facilities [Startup Researcher, September 2026] [Pulse 2.0, October 2026].
Demand drivers are easier to substantiate than market size. Several sources converge on the same picture: post-acute admissions still depend on manual review of large referral packets, with case managers sending extensive documentation while patients wait for placement [Digital Health Funding, September 2026] [Tom Stewart]. Basalt's reported result at Lifepoint, where median chart-processing time fell from 8.5 minutes to 1.2 minutes, is customer-specific and should not be generalized to the whole market, but it does show why buyers may fund this category even before broader enterprise AI budgets fully mature [Digital Health Funding, September 2026] [Startup Researcher, September 2026]. The additional reported rollout across 62 ScionHealth hospitals by the end of 2026, plus expected expansion into 49 additional Lifepoint markets, points to buyer interest in standardizing referral review across distributed footprints [Pulse 2.0, October 2026].
Adjacent markets widen the addressable territory, though most of that expansion remains a company plan rather than an observed result. Basalt has said it intends to move from admissions into discharge and payer workflows, which places it next to care-transition software, utilization management, benefits verification, and prior authorization tooling [Basalt Health, September 2026] [VentureBurn, September 2026] [HLTH, September 2026]. Those adjacencies matter because the referral packet is only one part of the broader throughput problem. If a vendor can turn unstructured clinical intake into a reliable workflow object, the same data path can plausibly support downstream authorization and placement tasks. That is still an inference from the product scope and company roadmap, not evidence of category capture.
Regulatory and macro forces cut in Basalt's favor, but they also raise the bar for execution. The favorable side is straightforward: healthcare providers continue to look for software that reduces administrative burden without removing clinician control, and Basalt's public positioning stresses that the system surfaces findings with source references while leaving the final decision to a clinician [Tom Stewart] [Basalt, retrieved 2026]. The constraint is that healthcare admissions workflows touch protected health information, payer rules, and facility-specific clinical criteria, so adoption tends to depend on trust, auditability, and integration discipline rather than model performance alone [HLTH, September 2026] [Basalt, retrieved 2026]. In practice, that makes this less a generic AI market than a regulated workflow software market that happens to use AI.
| Market lens | Public evidence | Read-through for Basalt |
|---|---|---|
| Core wedge | Referral packets arrive by fax, portal, or direct EMR integration and must be evaluated against facility criteria [HLTH, September 2026] | Suggests a fragmented intake layer with scope for workflow standardization |
| Buyer urgency | Patients can remain in hospital beds while case managers send large documentation packets for placement [Digital Health Funding, September 2026] | Supports a time-to-decision ROI case rather than a speculative AI spend case |
| Early multi-site demand | Deployment scaling across 62 ScionHealth hospitals by end-2026 [Pulse 2.0, October 2026] | Indicates relevance to system-level operators if rollout lands as reported |
| Category expansion | Company plans to extend into discharge and payer workflows [Basalt Health, September 2026] [VentureBurn, September 2026] | Points to adjacency upside, though still roadmap-level rather than proven market share |
The table shows why the opportunity is legible even without a formal TAM figure in the source set. The buying logic rests on throughput, staffing efficiency, and auditability inside a regulated handoff, which is often a stronger early signal than top-down market estimates.
Single-source, plausible -- This section relies on named public sources, but the material premises are drawn mainly from company announcement coverage and company-described product scope, with no independent third-party market sizing study in the provided evidence.
Who Else Is Fighting for This
MIXED Basalt is not competing in a clean greenfield so much as trying to displace a patchwork of manual intake work, EHR-adjacent workflow, and incumbent post-acute admissions software with a narrower AI-first layer focused on referral review and placement speed [Basalt, retrieved 2026] [HLTH, September 2026].
The immediate competitive map is clearer by category than by named company, because the source set does not identify direct rivals by name. At the incumbent end, the alternative is existing admissions and intake workflow inside post-acute operators, often tied to fax, portal, and EHR-driven document flow rather than a dedicated AI referral triage product [HLTH, September 2026] [Digital Health Funding, September 2026]. Adjacent substitutes include internal operations teams reviewing packets manually, as well as broader provider workflow tooling that can absorb parts of benefits verification or prior authorization without owning the full post-acute admissions decision path [HLTH, September 2026] [Tom Stewart]. In practice, that means Basalt is selling against labor, embedded process, and general-purpose health IT before it is selling against a well-documented set of venture-backed pure plays.
Where Basalt appears strongest today is in specificity. The product is described as reading referral packets from fax, web portal, or direct electronic medical record integration, checking them against facility-specific criteria, and surfacing findings with source references rather than automating the final clinical decision outright [HLTH, September 2026] [Tom Stewart]. That positioning matters because it narrows the implementation ask: a post-acute operator does not need to replace core clinical systems to test whether referral review can move faster. Reported traction with Lifepoint Health and ScionHealth gives the company a more credible wedge than a generic administrative AI pitch, including a reported reduction in median chart-processing time at Lifepoint from 8.5 minutes to 1.2 minutes and planned rollout across 62 ScionHealth hospitals by the end of 2026 [Digital Health Funding, September 2026] [Pulse 2.0, October 2026]. The edge is real if these deployments deepen, but it is still perishable. Workflow software in healthcare tends to invite fast imitation once an ROI case is visible, especially when the differentiation rests on packaging, implementation, and data handling more than on an obvious regulatory moat.
The company is most exposed where platform ownership sits elsewhere. Hospitals and post-acute operators already depend on EHRs, revenue cycle systems, and existing intake processes that can extend into adjacent tasks over time, and Basalt's own expansion plan into discharge and payer workflows moves it closer to categories with more established vendors and longer integration histories [Fundraise Insider, September 2026] [Basalt Health, September 2026]. That does not make expansion unattractive, but it does raise the bar. A narrow referral-review wedge can win early because it solves a painful bottleneck; turning that wedge into a broader operating layer requires proving that buyers will consolidate more workflow around Basalt rather than keep it as a point solution.
The most plausible 18-month scenario is a split outcome between workflow specialists and system-of-record vendors. Basalt is the likely winner if buyers continue to prefer lightweight overlays that reduce intake time without forcing a full system replacement, particularly in post-acute networks where fax-based and packet-based review is still common [Basalt, retrieved 2026] [Digital Health Funding, September 2026]. The likeliest loser in that case is the manual process itself, because the reported time compression at Lifepoint gives operators a concrete benchmark for what software-assisted review can do [Digital Health Funding, September 2026]. The reverse scenario is also straightforward: incumbent EHR-adjacent or admissions workflow vendors win if customers decide the safer path is to buy added automation from existing vendors rather than introduce another layer into a regulated intake process. With no named direct competitor verified in the source set, the near-term contest is less Basalt versus a single startup than Basalt versus buyer inertia and incumbent software budgets.
Single-source, plausible -- Based primarily on company materials and trade coverage; no named direct competitors were confirmed in the public source set, so category analysis is stronger than company-by-company corroboration.
Opportunity
PUBLIC
The prize here is not a faster admissions tool in isolation, but a credible shot at becoming the workflow layer that sits between acute-care discharge pressure and post-acute capacity, if Basalt can turn a narrow referral-review wedge into a broader operating system for placement, authorization, and payer handoffs [Basalt Health, September 2026] [HLTH, September 2026] [VentureBurn, September 2026].
The headline opportunity is straightforward. Hospitals and post-acute operators still move high-stakes patients through document-heavy, time-sensitive handoffs, and Basalt is targeting the point where delays are both operationally painful and visible to buyers. Public reporting ties the product to referral intake across fax, web portal, and direct electronic-medical-record integration, then to facility-specific admission review and downstream benefits-verification and prior-authorization workflows [HLTH, September 2026]. That matters because the company is not selling a general administrative assistant. It is selling into a specific bottleneck where one documented customer, Lifepoint Health, reportedly cut median chart-processing time from 8.5 minutes to 1.2 minutes, an 86% reduction [Digital Health Funding, September 2026]. If those gains hold across larger deployments, the outcome that comes into view is a default transaction layer for post-acute intake, first in admissions and then in adjacent discharge and payer workflows that management has already said it plans to enter [Basalt Health, September 2026] [Fundraise Insider, September 2026].
The path to scale is still conditional, but the public evidence supports several ways this could compound into a much larger business.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Regional post-acute standard | Basalt becomes the default admissions workflow across large multi-site post-acute operators, starting with behavioral health and expanding into broader post-acute categories | The September 2026 Series A gives the company capital to scale go-to-market and deployment, while reported rollouts across ScionHealth and Lifepoint create reference accounts [Basalt Health, September 2026] [Pulse 2.0, October 2026] | Basalt already has named enterprise deployment momentum, including scaling across 62 ScionHealth hospitals by end-2026 and expected expansion into 49 additional Lifepoint markets [Pulse 2.0, October 2026] |
| Discharge-to-placement infrastructure | Basalt extends from referral review into a system used earlier in discharge planning and later in payer coordination, increasing workflow ownership and budget capture | Product expansion into discharge and payer workflows, which the company and coverage both describe as the next step after admissions [Basalt Health, September 2026] [VentureBurn, September 2026] | The current product already touches adjacent tasks such as benefits verification and prior authorization, so the expansion is adjacent rather than a category reset [HLTH, September 2026] |
| Compliance-first AI layer for post-acute | Basalt becomes trusted software for clinical review teams because it pairs speed with source-linked evidence and a clinician-in-the-loop decision model | Broader market acceptance of AI tooling that does not replace the admission decision but supports it with cited findings [Tom Stewart] [Basalt, retrieved 2026] | Public materials consistently position the software as surfacing risks with source references and leaving the decision to clinicians, which is a more adoptable posture in regulated healthcare workflows [Tom Stewart] [Basalt, retrieved 2026] |
What compounding looks like is not a consumer-style network effect. It is workflow entrenchment. Basalt reads referral packets from multiple intake channels, evaluates them against facility-specific criteria, and feeds work that sits downstream of the initial document pass, including benefits verification and prior authorization [HLTH, September 2026]. Once that system is configured inside a provider's real operating process, the value of ripping it out rises because the product is no longer just summarizing charts, it is shaping how intake teams decide, document, and move patients. The early signs of that kind of entrenchment are the reported enterprise rollouts: live use at Lifepoint since the seed period, expansion into additional Lifepoint markets, and scaling across 62 ScionHealth hospitals by the end of 2026 [Startup Researcher, September 2026] [Pulse 2.0, October 2026]. A second layer of compounding could come from product scope. If the same system that handles admissions also becomes the handoff point for discharge and payer workflows, Basalt's account value and switching costs could rise together [Fundraise Insider, September 2026] [Basalt Health, September 2026].
The size of the win is harder to quantify from public evidence because no market-size source or close public comparable is included in the record here. Even so, the upside case can be framed concretely. Basalt has raised about $24.5 million in disclosed capital, including a $20 million Series A led by NEA, and is already being deployed across named health-system footprints rather than point pilots [Startup Researcher, September 2026] [Basalt Health, September 2026]. If the "Discharge-to-placement infrastructure" scenario plays out, the company could plausibly mature into a strategic software asset for a larger healthcare IT buyer or private-equity-backed platform seeking control over post-acute throughput and authorization workflows, with enterprise value potentially in the several-hundred-million-dollar range (scenario, not a forecast). That inference rests on role in workflow, customer footprint, and expansion surface, not on any disclosed valuation or revenue multiple in the public record [HLTH, September 2026] [Pulse 2.0, October 2026].
Single-source, plausible -- Relies on one company announcement and several trade-publisher reports, with partial corroboration across HLTH, Pulse 2.0, Startup Researcher, VentureBurn, and Digital Health Funding.
Sources
From the public record
[Basalt, retrieved 2026] Basalt · Post-acute admissions | https://basalt.health/
[Basalt Health, retrieved October 28] Jobs - Basalt Health | https://basalt.health/jobs
[VentureBurn, September 2026] Basalt Health Raises $20M to Expand AI Post-Acute Care Platform | https://ventureburn.com/2026/09/basalt-health-raises-20m-to-expand-ai-post-acute-care-platform/
[Fundraise Insider, September 2026] NEA Leads Basalt Health’s $20M Series A for Post-Acute Admissions | https://fundraiseinsider.com/nea-leads-basalt-healths-20m-series-a-for-post-acute-admissions/
[Basalt Health, September 2026] Basalt Health Raises $20M to Scale AI-Powered Post-Acute Care Platform | https://hlth.com/news/basalt-health-raises-20m-to-scale-ai-powered-post-acute-care-platform
[Startup Researcher, September 2026] Basalt Health Secures $20 Million Series A Led by NEA | https://startupresearcher.com/basalt-health-secures-20-million-series-a-led-by-nea/
[HLTH, September 2026] Basalt Health Raises $20M to Scale AI-Powered Post-Acute Care Platform | https://hlth.com/news/basalt-health-raises-20m-to-scale-ai-powered-post-acute-care-platform
[Pulse 2.0, October 2026] Basalt Health Raises $20 Million Series A Led By NEA | https://pulse2.com/basalt-health-raises-20-million-series-a-led-by-nea/
[Tom Stewart] Tom Stewart | https://tomstewart.com/
[Seedtable, 2026] Basalt Health | https://www.seedtable.com/startups/basalt-health
[Digital Health Funding, September 2026] Basalt Health Secures $20M to Speed Up Post-Acute Care… | https://digitalhealthfunding.com/basalt-health-secures-20m-to-speed-up-post-acute-care/
Articles about Basalt Health
- Basalt Health's AI Cuts Post-Acute Referral Times From 8.5 Minutes to 1.2 — The Nashville startup, founded by a former Accolade product builder, is scaling its admissions software across Lifepoint and ScionHealth facilities.